Antimicrobial activity of Ankaferd Blood Stopper® against nosocomial bacterial pathogens-Reference-Cited by-同舟云学术

Antimicrobial activity of Ankaferd Blood Stopper® against nosocomial bacterial pathogens

Published:2010-04-01 Issue:2 Volume:5 Page:198-202
ISSN:2391-5463
Container-title:Open Medicine
language:
Short-container-title:

Author:

Saribas Zeynep¹,Sener Burcin¹,Haznedaroglu Ibrahim²,Hascelik Gulsen¹,Kirazli Serafettin³,Goker Hakan²

Affiliation:

1. 1Department of Microbiology and Clinical Microbiology, Hacettepe University Faculty of Medicine, 06100, Ankara, Turkey

2. 2Department of Hematology, Hacettepe University Faculty of Medicine, 06100, Ankara, Turkey

3. 3Department of Research and Development, Ankaferd Drug Inc., 34820, Istanbul, Turkey

Abstract

AbstractThe aim of this study is to investigate the in vitro antimicrobial activity of Ankaferd Blood Stopper® against methicillin-resistant Staphylococcus aureus (MRSA), Enterococcus species, Escherichia coli, Pseudomonas species, Acinetobacter species and Klebsiella species of nosocomial origin. Ankaferd inhibited growth in 72.4% to 100% of the bacteria tested, depending on the type of the isolate. As a result, it can be stated that Ankaferd inhibits the in vitro growth of nosocomial bacteria. This is a novel, important finding since severe hospital infections coexist with many hemostatic disorders, and the use of Ankaferd may increase hemostatic potential in such clinical conditions.

Publisher

Walter de Gruyter GmbH

Subject

General Medicine

Link

http://link.springer.com/content/pdf/10.2478/s11536-009-0140-4.pdf

Reference31 articles.

1. Goker H., Haznedaroglu I.C., Ercetin S., Kirazli S., Akman U., Ozturk Y., Firat, H.C. Haemostatic actions of the folkloric medicinal plant extract Ankaferd Blood Stopper, J. Int. Med. Res., 2008, 36, 163–170

2. www.ankaferd.com

3. Arslan S., Haznedaroglu I.C., Oz B., Goker, H., Endobronchial application of Ankaferd blood stopper to control profuse lung bleeding leading to hypoxemia and hemodynamic instability, Respir. Med., 2009, 2, 144–146

4. Dogan O.F., Ozyurda U., Uymaz O.K., Ercetin S., Haznedaroglu I. New anticoagulant agent for CABG surgery, Eur J Clin Invest, 2008, 38, 341–341

5. Ibis M., Kurt M., Onal I.K., Haznedaroglu I.C., Successful management of bleeding due to solitary rectal ulcer via topical application of Ankaferd blood stopper, J Altern Complement Med, 2008, 14, 1073–1074

Cited by 29 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pharmacobiology of topical Ankaferd hemostat in neoplastic disorders;The European Research Journal;2023-09-04

2. Antitumor activity of Ankaferd Blood Stopper® on MCF-7 breast cancer: A proteomic approach to ascertain the mechanism of the action;Journal of Herbal Medicine;2021-08

3. The effect of Ankaferd blood stopper on liver damage in experimental obstructive jaundice;TURKISH JOURNAL OF MEDICAL SCIENCES;2021-06-28

4. Ankaferd hemostat (ABS) as a potential mucosal topical agent for the management of COVID-19 syndrome based on its PAR-1 inhibitory effect and oestrogen content;Medical Hypotheses;2020-10

5. Ankaferd Hemostat Affects Etoposide Resistance of the Malignant Melanoma Cells;UHOD-ULUSLAR HEMATOL;2020